The adjuvant can reduce the amount of vaccine required per dose, allowing more people to be immunized, and create longer-lasting immunity, Glaxo said PARIS/LONDON : GlaxoSmithKline Plc plans to produce 1 billion doses of a vaccine adjuvant -- a booster that can help any brand of shot -- to support immunization against the Covid-19 pandemic next year.
The adjuvant can reduce the amount of vaccine required per dose, allowing more people to be immunized, and create longer-lasting immunity, Glaxo said in a statement Thursday.
The UK drugmaker in April agreed to provide its technology to help develop an experimental vaccine with French pharma giant Sanofi.